TITLE

Recently Approved

PUB. DATE
July 2008
SOURCE
Pharmaceutical Representative;Jul2008, Vol. 13 Issue 7, p14
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the newly approved drugs by the U.S. Food and Drug Administration (FDA). The FDA approved Otsuka America Pharmaceutical's Abilify as an adjunctive therapy for manic and mixed episodes related with bipolar I disorder, with or without psychotic features in adults. The Advair Diskus 250/50 of GlaxoSmithKline was cleared for the reduction of exacerbations chronic obstructive pulmonary disease patients. The OraVerse injection was approved for soft-tissue anesthesia reversal. INSET: Digitek recalled.
ACCESSION #
32996759

 

Related Articles

  • Panel: Forest, Nycomed COPD Drug Not Ready for Prime Time. Young, Donna // BioWorld Today;4/8/2010, Vol. 21 Issue 67, p1 

    The article reports that the Pulmonary-Allergy Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) did not give approval to Forest Laboratories Inc. and Nycomed GmbH for their drug against chronic obstructive pulmonary disease (COPD) called Daxas. The panel earlier declared...

  • FDA OKs Narrower Indication for Forest Lab's COPD Drug. Powers, Marie // BioWorld Today;3/2/2011, Vol. 22 Issue 41, p1 

    The article reports on the approval granted by the U.S. Food and Drug Administration (FDA) to Forest Laboratories Inc. to market its Daliresp drug in the U.S. which aims to reduce the risk of chronic obstructive pulmonary disease (COPD). Forest has licensed the drug in 2009 from Nycomed GmbH of...

  • 'Lung' Time Coming: Breo Win Caps Theravance, GSK Efforts. Osborne, Randy // BioWorld Today;5/13/2013, Vol. 24 Issue 91, p1 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) for Breo (fluticasone furoate/vilanterol) for long-term treatment for chronic pulmonary obstructive disease from GlaxoSmithKline pPLC and Theravance Inc. which will be launched in the third quarter of 2013 under...

  • Opinion Forest: novel COPD therapy faces US setback.  // PharmaWatch: Monthly Review;May2010, Vol. 9 Issue 5, p11 

    In this article, the author discusses the 10-5 vote made by the U.S. Food and Drug Administration (FDA) advisory panel against the approval of Forest Laboratories Inc.' Daxas for the treatment of chronic obstructive pulmonary disease. The author notes that the advisory panel raised concerns on...

  • Spiriva gains indication.  // Monthly Prescribing Reference;Jan2010, Vol. 26 Issue 1, pA12 

    The article reports that the U.S. Food and Drug Administration (FDA) has approved the drug Spiriva HandiHaler from Boehringer Ingelheim GmbH and Pfizer Inc. as treatment for chronic obstructive pulmonary disease (COPD).

  • Roflumilast: An oral agent for severe COPD. Tanzi, Maria G. // Pharmacy Today;Apr2011, Vol. 17 Issue 4, p34 

    The article reports on the approval of the oral drug Roflumilast from Forest Pharmaceutical Inc. by the U.S. Food and Drug Administration to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations. It notes that the drug's clinical trial program involved more than 9,000...

  • Drugs in the News.  // Clarendon Enterprise (TX);8/16/2012, Vol. 23 Issue 33, p10 

    The article presents information that the U.S. Food and Drug Administration has approved the drug Tudorza Pressair for the treatment of chronic obstructive pulmonary disease (COPD).

  • Umeclidinium bromide/vilanterol trifenatate, perampanel, and eslicarbazepine acetate. Hussar, Daniel A.; Dharsi, Nabil // Journal of the American Pharmacists Association: JAPhA;Jul/Aug2014, Vol. 54 Issue 4, p450 

    The article offers information on new drugs approved by the U.S. Food and Drug Administration, as of August 2014. Topics include the risks and precautions with the use of umeclidinium bromide for treating chronic obstructive pulmonary disease and the concerns with the use of two antiepileptic...

  • FDA approves Arcapta Neohaler to treat chronic obstructive pulmonary disease.  // Biomedical Market Newsletter;7/5/2011, p4 

    The article reports that on July 1, 2011, Arcapta Neohaler was approved by the U.S. Food and Drug Administration (FDA) for treatment of people suffering from airflow obstruction caused by chronic obstructive pulmonary disease (COPD). It says that Arcapta Neohaler relaxes muscles around the...

  • Drug Watch.  // Formulary;Mar2004, Vol. 39 Issue 3, p186 

    Focuses on drugs for the treatment of chronic obstructive pulmonary disease in the United States. Drug name; Indications; Drug development setbacks; Approval status from the Food and Drug Administration.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics